ATARA BIOTHERAPEUTICS, INC. Operating Lease, Payments
ATARA BIOTHERAPEUTICS, INC. (ATRA) reported Operating Lease, Payments of $482.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Cash Flow › Other Cash Flow Items
us-gaap:OperatingLeasePayments · last filed 2026-08-12
- ATARA BIOTHERAPEUTICS, INC. operating lease, payments for the quarter ending 2026-06-30 was $176.00K, a 82.19% decline year-over-year.
- ATARA BIOTHERAPEUTICS, INC. operating lease, payments for the quarter ending 2026-03-31 was $306.00K, a 92.61% decline year-over-year.
- ATARA BIOTHERAPEUTICS, INC. operating lease, payments for the quarter ending 2025-12-31 was $506.00K, a 87.40% decline year-over-year.
- ATARA BIOTHERAPEUTICS, INC. operating lease, payments for the quarter ending 2025-09-30 was $870.00K, a 78.30% decline year-over-year.
- ATARA BIOTHERAPEUTICS, INC. operating lease, payments for fiscal 2025 was $6.50M, a 59.40% decline from fiscal 2024.
- ATARA BIOTHERAPEUTICS, INC. operating lease, payments for fiscal 2024 was $16.02M, a 3.85% decline from fiscal 2023.
- ATARA BIOTHERAPEUTICS, INC. operating lease, payments for fiscal 2023 was $16.66M, a 24.17% increase from fiscal 2022.
- ATARA BIOTHERAPEUTICS, INC. operating lease, payments for fiscal 2022 was $13.42M, a 258.94% increase from fiscal 2021.
| Period end | Operating Lease, Payments 3 month | Operating Lease, Payments 6 month | Operating Lease, Payments 9 month | Operating Lease, Payments 12 month |
|---|---|---|---|---|
| 2026-06-30 | $176.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-12 | $482.00K 10-Q · filed 2026-08-12 | $988.00K derived: sum of 3 quarters · filed 2026-08-12 | $1.86M derived: sum of 4 quarters · filed 2026-08-12 |
| 2026-03-31 | $306.00K 10-Q · filed 2026-05-12 | $812.00K derived: sum of 2 quarters · filed 2026-05-12 | $1.68M derived: sum of 3 quarters · filed 2026-05-12 | $2.67M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-12-31 | $506.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-16 | $1.38M derived: sum of 2 quarters · filed 2026-03-16 | $2.36M derived: sum of 3 quarters · filed 2026-08-12 | $6.50M 10-K · filed 2026-03-16 |
| 2025-09-30 | $870.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | $1.86M derived: sum of 2 quarters · filed 2026-08-12 | $6.00M 10-Q · filed 2025-11-12 | $10.01M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-06-30 | $988.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-12 | $5.13M 10-Q · filed 2026-08-12 | $9.14M derived: sum of 3 quarters · filed 2026-08-12 | $13.15M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-03-31 | $4.14M 10-Q · filed 2026-05-12 | $8.16M derived: sum of 2 quarters · filed 2026-05-12 | $12.16M derived: sum of 3 quarters · filed 2026-05-12 | $16.16M derived: sum of 4 quarters · filed 2026-05-12 |
| 2024-12-31 | $4.02M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-16 | $8.03M derived: sum of 2 quarters · filed 2026-03-16 | $12.03M derived: sum of 3 quarters · filed 2026-03-16 | $16.02M 10-K · filed 2026-03-16 |
| 2024-09-30 | $4.01M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | $8.01M derived: sum of 2 quarters · filed 2025-11-12 | $12.00M 10-Q · filed 2025-11-12 | |
| 2024-06-30 | $4.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-11 | $7.99M 10-Q · filed 2025-08-11 | ||
| 2024-03-31 | $3.99M 10-Q · filed 2025-05-15 | |||
| 2023-12-31 | $16.66M 10-K · filed 2025-03-07 | |||
| 2022-12-31 | $2.91M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-28 | $7.04M derived: sum of 2 quarters · filed 2024-03-28 | $13.42M 10-K · filed 2024-03-28 | |
| 2022-09-30 | $4.13M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-08 | $10.50M 10-Q · filed 2022-11-08 | ||
| 2022-06-30 | $6.37M 10-Q · filed 2022-08-08 | |||
| 2021-12-31 | $1.22M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-08 | $2.16M derived: sum of 2 quarters · filed 2023-02-08 | $3.74M 10-K · filed 2023-02-08 | |
| 2021-09-30 | $935.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-08 | $2.52M 10-Q · filed 2022-11-08 | ||
| 2021-06-30 | $1.58M 10-Q · filed 2022-08-08 | |||
| 2020-12-31 | $2.88M 10-K · filed 2023-02-08 | |||
| 2019-12-31 | $650.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-28 | $1.25M derived: sum of 2 quarters · filed 2022-02-28 | $1.69M derived: sum of 3 quarters · filed 2022-02-28 | $2.35M 10-K · filed 2022-02-28 |
| 2019-09-30 | $598.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-07 | $1.04M derived: sum of 2 quarters · filed 2019-11-07 | $1.70M 10-Q · filed 2019-11-07 | |
| 2019-06-30 | $444.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-08 | $1.10M 10-Q · filed 2019-08-08 | ||
| 2019-03-31 | $654.00K 10-Q · filed 2019-05-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Pelthos Therapeutics Inc. (PTHS) | United States | $0.086B | -1.20 |
| COGNITION THERAPEUTICS INC (CGTX) | United States | $0.090B | -6.52 |
| Vaxart, Inc. (VXRT) | United States | $0.080B | 3.84 |
| Kalaris Therapeutics, Inc. (KLRS) | United States | $0.073B | -2.19 |
| Cardiff Oncology, Inc. (CRDF) | United States | $0.101B | -2.22 |
| CHAMPIONS ONCOLOGY, INC. (CSBR) | United States | $0.070B | -68.02 |
| BioStem Technologies, Inc. (BSEM) | United States | $0.069B | |
| Eloxx Pharmaceuticals, Inc. (ELOX) | United States | $0.065B | |
| Black Diamond Therapeutics, Inc. (BDTX) | United States | $0.109B | -2.48 |
| MiNK Therapeutics, Inc. (INKT) | United States | $0.063B | -5.37 |